Cycle Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Cycle Pharmaceuticals's estimated annual revenue is currently $23.7M per year.
- Cycle Pharmaceuticals's estimated revenue per employee is $201,000
- Cycle Pharmaceuticals's total funding is $25M.
Employee Data
- Cycle Pharmaceuticals has 118 Employees.
- Cycle Pharmaceuticals grew their employee count by 42% last year.
Cycle Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Global Regulatory Affairs | Reveal Email/Phone |
2 | VP, US Sales | Reveal Email/Phone |
3 | Director Sales, East | Reveal Email/Phone |
4 | Senior Director, Product Development & Regulatory Affairs | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | General Counsel & HR Director | Reveal Email/Phone |
7 | SVP & Chief Commercial Officer | Reveal Email/Phone |
8 | Quality Assurance Officer | Reveal Email/Phone |
9 | Supply Chain Director | Reveal Email/Phone |
10 | Clinical Education Manager | Reveal Email/Phone |
Cycle Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Cycle Pharmaceuticals?
Innovation. Transformation. Treatment, reimagined. We reimagine how orphan drugs can benefit patients with rare diseases, to make their lives easier and improve their quality of life at every stage. By optimising and enhancing treatments, improving efficacy, identifying new indications for drugs, and reintroducing products to the market, we give patients the options they need. Cycle has three core areas of pharmaceutical development: improving drugs ￃﾢ￢ﾂﾬ￢ﾀﾜ optimising an existing drug; repurposing drugs ￃﾢ￢ﾂﾬ￢ﾀﾜ creating a new indication for an already existing drug; and generics ￃﾢ￢ﾂﾬ￢ﾀﾜ reinstating generic drugs, previously available in the market. These three areas of focus are underpinned by formulation technology ￃﾢ￢ﾂﾬ￢ﾀﾜ creating new drug delivery technologies to improve the efficacy and effectiveness of drugs, allowing us to give patients greater freedom and choice.
keywords:N/A
$25M
Total Funding
118
Number of Employees
$23.7M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cycle Pharmaceuticals News
Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted ... these symptoms toward the end of their treatment cycle.
WFC, Vertex Pharmaceuticals Inc. VRTX and Canadian Pacific Railway Limited ... The sampe of results at this stage of the reporting cycle is...
The major players covered in Nitisinone Markets: Sobi; Cycle Pharmaceuticals. Nitisinone Market Breakdown by Type: Orfadin; NITYR. Nitisinone...
Cycle Pharmaceuticals secures $25 million debt financing 08-09-2020 Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that it has executed a definitive agreement for a $25 millio ...
Cycle Pharmaceuticals secures $25 million debt financing 08-09-2020 Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that it has executed a definitive agreement for a $25 millio ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 118 | 24% | $16.7M |
#2 | $38.1M | 118 | 7% | N/A |
#3 | $18.3M | 118 | -3% | $265M |
#4 | $18.3M | 118 | 23% | N/A |
#5 | $24.3M | 119 | 5% | N/A |